CLINICAL TRIAL: IMPAACT 1065 PHASE I/II STUDY OF SAFETY AND IMMUNOGENICITY OF Q

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 摘要 FDA最近批准的四价脑膜炎球菌结合疫苗（MCV 4）已导致建议在青春期前访问时接种11-12岁的个体，进入高中（约15岁）的个体和住在宿舍的新生，认识到青春期期间脑膜炎球菌疾病风险增加。 由于大多数围产期获得性HIV感染的儿童已进入青春期，并且美国大多数新发儿科HIV感染发生在青少年年龄组，因此针对脑膜炎球菌免疫接种患者的新的基于年龄的建议将导致大多数HIV感染的青少年符合接种疫苗的年龄条件，而HIV感染人群没有安全性或免疫原性数据。 这项I/II期研究将在296名11 - 15岁的HIV感染青年中评价MCV-4的安全性和免疫原性;估计MCV-4疫苗在HIV-1感染青年中的长期（72周）免疫原性;评价MCV-4疫苗在HIV-1感染青年中的安全性，包括接种疫苗后的短期局部和全身反应。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. ABSTRACT The recent approval by the FDA of the quadrivalent meningococcal conjugate vaccine (MCV4) has led to a recommendation to vaccinate 11-12 year-old individuals at a pre-adolescent visit, individuals entering high school (approximately 15 years of age) and incoming college freshman living in dormitories, in recognition of the increased meningococcal disease risk during adolescence. As the majority of children with perinatally acquired HIV infection have aged into adolescence, and the majority of new pediatric HIV infections in the US are occurring in the adolescent age group, the new age-based recommendations for meningococcal immunization patients will lead to most HIV-infected youth being age-eligible for a vaccine for which there are no safety or immunogenicity data available from HIV-infected populations. This phase I/II study will evaluate the safety and immunogenicity of MCV-4 in 296 HIV-infected youth between =11 and 15); To estimate the long-term (at 72 weeks) immunogenicity of the MCV4 vaccine in HIV-1 infected youth; To evaluate the safety of the MCV4 vaccine in HIV-1 infected youth, including short-term local and systemic reactions following administration of the vaccine.